RESUMO
BACKGROUND: Premedication administration to patients who are to receive blood transfusions continues despite evidence of a lack of benefit when given to prevent febrile nonhemolytic or mild allergic transfusion reactions. Reviews of ordering practices and staff surveys on an adult inpatient hematology-oncology unit in our multisite oncology medical center indicated a lack of standardization and overuse of premedication in blood transfusions and a lack of knowledge of when it was appropriate to use premedication. METHODS: A literature search was performed, and the evidence led to a proposal for a quality improvement (QI) project focused on development of an evidence-based algorithm to guide clinicians in when to administer which premedication, development of clear documentation for premedication plans, integration of the documented premedication plans into electronic orders for blood products, and staff education. Interventions included a hospital-wide algorithm and an electronic order to be integrated with a premedication plan for each patient on the adult hematology-oncology unit. RESULTS: Seven months after implementation of the intervention, premedication use among patients decreased by 57.6%, and the transfusion reaction rate decreased from 1% to 0.8%. Staff knowledge as measured by responses to pre- and postintervention surveys on the appropriate use of premedication also improved. CONCLUSION: Evidence-based interventions can reduce the incidence of premedication use in patients receiving blood transfusions.
Assuntos
Pré-Medicação , Melhoria de Qualidade , Humanos , Pré-Medicação/métodos , Transfusão de Sangue/normas , Reação Transfusional/prevenção & controle , Algoritmos , AdultoRESUMO
BACKGROUND: Laparoscopic cholecystectomy is a proper treatment for cholecystitis but the Carbon dioxide gas which is used in surgery stimulates the sympathetic system and causes hemodynamic changes and postoperative shivering in patients undergoing operations. This study was conducted to evaluate the effects of clonidine on reducing hemodynamic changes during tracheal intubation and Carbon dioxide gas insufflation and postoperative shivering in patients undergoing laparoscopic cholecystectomy. MATERIAL AND METHODS: This prospective, randomized, triple-blind clinical trial was conducted on 60 patients between the 18-70 years-old age group, who were candidates of laparoscopic cholecystectomy surgery. The patients randomized into two groups (30 patients received 150 µg oral clonidine) and 30 patients received 100 mg oral Vitamin C). Heart rate and mean arterial pressure of patients were recorded before anesthesia, before and after laryngoscopy, before and after Carbon dioxide gas insufflation. Data were analyzed using Chi-2, student t-test, and analysis of variance by repeated measure considering at a significant level less than 0.05. RESULTS: The findings of this study showed that both heart rate and mean arterial pressure in clonidine group after tracheal intubation and Carbon dioxide gas insufflation were lower than patients in the placebo group, but there was not any statistically significant difference between the two groups (p>0.05) and also postoperative shivering was not different in groups. There was no significant statistical difference in postoperative shivering between the two groups (p>0.05). CONCLUSION: Using 150 µg oral clonidine as a cheap and affordable premedication in patients undergoing laparoscopic cholecystectomy improves hemodynamic stability during operation.
Assuntos
Colecistectomia Laparoscópica , Insuflação , Humanos , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso , Clonidina/uso terapêutico , Clonidina/farmacologia , Colecistectomia Laparoscópica/efeitos adversos , Insuflação/efeitos adversos , Estremecimento , Dióxido de Carbono/farmacologia , Estudos Prospectivos , Hemodinâmica , Pré-Medicação , IntubaçãoRESUMO
Pre-emptive analgesia consists of administering drugs such as opioids and nonsteroid anti-inflammatory drugs. This study aims to evaluate the intraoperative antinociceptive effects of diclofenac administered alone in premedication or combined with morphine along with its potential influence on recovery of dogs undergoing ovariohysterectomy. A total of 34 dogs (ASA I or II) admitted for ovariohysterectomy were randomly allocated into three groups according to the drugs given in premedication: Diclofenac (D) (n = 11), Morphine (M) (n = 13) and Diclofenac-Morphine (DM) (n = 10) groups. Induction and maintenance of anesthesia were standardized in all dogs. To assess intraoperative nociception, the heart rate (HR) and mean arterial pressure (MAP) were recorded during the surgery and at predefined time points: St (steady-state), Cut (cutaneous incision), P1 (first ovarian manipulation), P2 (second ovarian manipulation) and Cerv (cervical manipulation). The dynamic variation of HR (ΔHR) and MAP (ΔMAP) over 2 min was calculated at each time point. After extubation, early quality of recovery was assessed. Compared to St, a significant increase in HR and MAP at P1, P2 and Cerv was shown in all groups. MAP in the M group was lower at St than in the other groups. The dynamic variation of HR (ΔHR) and MAP (ΔMAP) was significantly less important at P2 and Cerv compared to P1 only in the DM group. Also, a better quality of recovery was shown in the D group compared to the M and DM groups. Diclofenac may be considered a suitable premedication drug and a part of a multimodal anesthetic approach in dogs.
Assuntos
Analgésicos Opioides , Diclofenaco , Animais , Cães , Feminino , Analgésicos Opioides/farmacologia , Analgésicos Opioides/uso terapêutico , Diclofenaco/farmacologia , Histerectomia/veterinária , Morfina/farmacologia , Ovariectomia/veterinária , Pré-Medicação/veterinária , Distribuição AleatóriaRESUMO
Purpose: Dexmedetomidine (Dex) is a potent and highly selective α2-adrenergic receptor agonist. Within an appropriate dose range, Dex can effectively attenuate the surgical stress response, provide intraoperative hemodynamic stability, and improve the patient recovery quality. High-dose Dex can delay patient awakening from anesthesia and increase the incidence of bradycardia. This randomized controlled trial aimed to investigate the effects of low-dose intravenous Dex premedication in patients undergoing laparoscopic cholecystectomy (LC). Material and Methods: In total, 100 patients undergoing LC were equally randomized into Group C (premedication with saline) and Group D (premedication with 0.5 µg/kg Dex). The patients were premedicated with saline or Dex, depending on the group, before anesthesia induction. Following this, anesthesia induction and endotracheal intubation was performed, and anesthesia was maintained during surgery. Following the completion of the surgery, the patients were transferred the post-anesthesia care unit (PACU) and stayed there until they met the PACU discharge criteria. The hemodynamic parameters, consumption of anesthetics, surgical duration, postoperative awakening time, extubation time, postoperative pain, and complications were recorded. Results: No significant differences were observed in the heart rate (HR) and mean arterial pressure (MAP) between the two groups before premedication (P>0.05). The MAP and HR immediately after endotracheal intubation and immediately after extubation were significantly lower in Group D than in Group C (P<0.05 for both). The incidence of bradycardia was significantly higher in Group D than in Group C (P<0.05), while atropine was used in neither group. Propofol and remifentanil consumption was significantly lower in Group D than in Group C (P<0.05). The postoperative awakening and extubation times were significantly shorter in Group D than in Group C (P<0.05). The postoperative visual analog scale scores for pain and incidence of nausea, vomiting, and cough were significantly lower in Group D than in Group C (P<0.05 for all). Conclusion: Our data suggest that premedication with dexmedetomidine (0.5 µg/kg) before general anesthesia induction can effectively attenuate intraoperative stress response and postoperative pain, maintain perioperative hemodynamic stability, and decrease the incidence of adverse events, which might be an effective and safe anesthetic protocol during LC worthy of further clinical application.
Assuntos
Colecistectomia Laparoscópica , Dexmedetomidina , Humanos , Bradicardia/induzido quimicamente , Estudos Prospectivos , Anestesia Geral , Dor Pós-Operatória/tratamento farmacológico , Pré-Medicação/métodos , Método Duplo-CegoRESUMO
OPINION STATEMENT: Monoclonal antibody (mAb) therapy is now considered a main component of cancer therapy in Australia. Although traditionally thought of as pure signalling inhibitors, a large proponent of these medications function through antibody-dependent cell-mediated cytotoxicity (ADCC). Currently, most protocols and institutional guidelines for ADCC-mediated mAbs promote the use of corticosteroids as premedication: this is implemented to reduce infusion-related reactions (IRRs) and antiemesis prophylaxis and combat concurrently administered chemotherapy-related syndromes. Concerningly, the inhibitory effects of ADCC by corticosteroids are well documented; henceforth, it is possible the current standard of care is misaligned to the literature surrounding ADCC. Subsequently, clinicians' decisions to act in contrast to this literature may be reducing the efficacy of mAbs. The literature suggests that the redundant use of corticosteroids should be cautioned against when used in conjunction with ADCC-mediated mAbs-this is due to the consequent reduction in anti-tumour activity. Owing to the fact IRRs typically occur upon initial infusion, the authors advocate for individual clinicians and institutional protocols to considering augmenting their practice to corticosteroid premedication at the first dose only, unless clinically indicated. Additionally, product information (PI) and consumer medicine information (CMI) documents distributed by Australian and international regulatory agencies should consider disclosing the risk of concurrent steroids with these medications. Moreover, the authors suggest considering alternative medications for the management of side effects.
Assuntos
Anticorpos Monoclonais , Esteroides , Humanos , Linhagem Celular Tumoral , Austrália , Anticorpos Monoclonais/efeitos adversos , Pré-Medicação , CorticosteroidesRESUMO
OBJECTIVES: This study aimed to confirm whether premedication with pronase before endoscopy improves mucosal visualization and increases precancerous lesion and cancer lesion detection rates. MATERIALS AND METHODS: From June 2018 to April 2019, out-patients scheduled for endoscopy from 13 hospitals were screened to be randomly allocated in a 2:1 ratio to premedication with pronase (group A) and water (group B). The primary endpoint was mucosal visibility scores, and the secondary endpoint was precancerous and cancer lesion detection rates. This trial was registered at Chinese Clinical Trial Registry, and the registration number was ChiCTR1800016853. RESULTS: Group A showed significantly lower mucosal visibility scores (better mucosal visibility) of esophagus, stomach, and duodenum than group B, with all P -values <0.001. The overall cancer detection rates between group A and group B were 0.83 and 1.08%, and overall detection rates of precancerous and cancer lesion were 4.4 and 4.9%, both without significant difference ( P =1.000 and 0.824). In addition, the flushing volume (milliliter) of group A (10.52±23.41) was less than group B (36.30±52.11) ( P <0.001), and the flushing frequency of group A (0.46±1.01) was fewer than group B (1.62±2.12) ( P <0.001). CONCLUSIONS: Premedication with pronase could achieve better mucosal visibility and decrease flushing frequency and volume, but may not increase lesion detection rates.
Assuntos
Endoscopia Gastrointestinal , Lesões Pré-Cancerosas , Humanos , Pronase/uso terapêutico , Estudos Prospectivos , Pré-MedicaçãoRESUMO
For children with cancer, blood product transfusions are crucial, but can be complicated by transfusion reactions. To prevent these complications, premedication is often given, although not always evidence-based. Herein, we describe a significant decrease in the use of premedication (72%-28%) at our institution after the implementation of standardized guidelines, without an increase in transfusion reactions (3.2% prior vs. 1.5% after standardization). Importantly, there were no severe transfusion reactions leading to hospitalization or death. Our results provide evidence in favor of more judicious use of premedication prior to transfusions in patients 21 years and younger being treated for cancer.
Assuntos
Neoplasias , Reação Transfusional , Criança , Humanos , Melhoria de Qualidade , Transfusão de Sangue , Neoplasias/terapia , Pré-MedicaçãoRESUMO
STUDY OBJECTIVE: To evaluate the association between midazolam premedication and postoperative delirium in a large retrospective cohort of patients ≥70 years. DESIGN: Retrospective cohort study. SETTING: A single tertiary academic medical center. PATIENTS: Patients ≥70 years having elective non-cardiac surgery under general anesthesia from 2020 to 2021. INTERVENTIONS: Midazolam premedication, defined as intravenous midazolam administration prior to induction of general anesthesia. MEASUREMENTS: The primary outcome, postoperative delirium, was a collapsed composite outcome including at least one of the following: a positive 4A's test during post-anesthesia care unit stay and/or the initial 2 postoperative days; physician or nursing records reporting new-onset confusion as captured by the CHART-DEL instrument; or a positive 3D-CAM test. The association between midazolam premedication and postoperative delirium was assessed using multivariable logistic regression, adjusting for potential confounding variables. As secondary analysis, we investigated the association between midazolam premedication and a composite of other postoperative complications. Several sensitivity analyses were performed using similar regression models. MAIN RESULTS: In total, 1973 patients were analyzed (median age 75 years, 47% women, 50% ASA score ≥ 3, 32% high risk surgery). The overall incidence of postoperative delirium was 15.3% (302/1973). Midazolam premedication was administered to 782 (40%) patients (median [IQR] dose 2 [1,2] mg). After adjustment for potential confounding variables, midazolam premedication was not associated with increased odds of postoperative delirium, with adjusted odds ratio of 1.09 (95% confidence interval 0.82-1.45; P = 0.538). Midazolam premedication was also not associated with the composite of other postoperative complications. Furthermore, no association was found between midazolam premedication and postoperative delirium in any of the sensitivity analyses preformed. CONCLUSIONS: Our results suggest that low doses of midazolam can be safely used to pre-medicate elective surgical patients 70 years or older before non-cardiac surgery, without significant effect on the risk of developing postoperative delirium.
Assuntos
Delírio do Despertar , Midazolam , Humanos , Feminino , Idoso , Masculino , Midazolam/efeitos adversos , Delírio do Despertar/epidemiologia , Delírio do Despertar/prevenção & controle , Delírio do Despertar/induzido quimicamente , Estudos Retrospectivos , Pré-Medicação , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/prevenção & controleRESUMO
RESUMO Objetivo: Avaliar o efeito do colírio de brimonidina 0,2% na redução da hiperemia e do sangramento ocular durante as cirurgias de estrabismo, em comparação com o colírio de nafazolina 0,025% + feniramina 0,3%. Métodos: Foram avaliados 14 pacientes com estrabismo e indicação de correção cirúrgica bilateral. Foi instilado antes do procedimento, de forma aleatória, um colírio em cada olho dos pacientes avaliados. A análise subjetiva da hiperemia conjuntival e do sangramento perioperatório foi realizada de forma duplo-cega, por dois cirurgiões. A avaliação objetiva do nível de hiperemia conjuntival foi realizada por análise das imagens obtidas por meio do software ImageJ®. Resultados: A análise de modelos multivariados de efeito misto indicou diferenças estatisticamente significantes entre os grupos em relação à hiperemia (avaliador 2) e ao sangramento intraoperatório (avaliadores 1 e 2), com maiores escores nos casos tratados com colírio de nafazolina + feniramina. Entretanto, não houve diferença estatística na análise objetiva realizada por meio da saturação de cores obtidas pelo programa ImageJ®. Conclusão: O colírio de brimonidina pode ser superior ao colírio de nafazolina + feniramina na redução do sangramento, levando-se em conta apenas a análise subjetiva.
ABSTRACT Objective: To evaluate the effect of 0.2% brimonidine eye drops in reducing hyperemia and ocular bleeding during strabismus surgeries, in comparison with 0.025% naphazoline + 0.3% pheniramine eye drops. Methods: Fourteen patients with strabismus and indication for bilateral surgical correction were evaluated. Before the procedure, the eye drops were instilled randomly in each eye of the evaluated patients. The subjective analysis of conjunctival hyperemia and perioperative bleeding was performed in a double-blind manner, by 02 surgeons. The objective assessment of the level of conjunctival hyperemia was performed by analyzing the images obtained using the ImageJ® software. Results: The analysis of multivariate mixed effect models indicated statistically significant differences between the groups in relation to hyperemia (rater 2) and intraoperative bleeding (raters 1 and 2) with higher scores in cases treated with naphazoline + pheniramine eye drops. However, there were no statistically significant differences in the objective analysis of color saturation obtained by the ImageJ® program. Conclusion: Brimonidine eye drops may be superior to naphazoline + pheniramine eye drops in reducing bleeding, taking into account the subjective analysis only.
Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Adulto , Feniramina/administração & dosagem , Hemorragia Ocular/prevenção & controle , Estrabismo/cirurgia , Tartarato de Brimonidina/administração & dosagem , Hiperemia/prevenção & controle , Complicações Intraoperatórias/prevenção & controle , Nafazolina/administração & dosagem , Soluções Oftálmicas/administração & dosagem , Pré-Medicação , Procedimentos Cirúrgicos Oftalmológicos/métodos , Vasoconstrição/efeitos dos fármacos , Fotografação , Método Duplo-Cego , Administração Tópica , Agonistas de Receptores Adrenérgicos alfa 2/administração & dosagem , Hemostasia Cirúrgica/métodosRESUMO
Introduction: perioperative anxiety in children may lead to psychological and physiological side effects. Clonidine is in increasing use in the pediatric population as an anxiolytic, sedative, and analgesic because of its central alpha2-adrenergic agonist effect. Our study aimed to evaluate the effect of clonidine in the prevention of perioperative children´s anxiety. Methods: we conducted a prospective controlled randomized double-blinded clinical trial including children aged between 2 and 15 years undergoing tonsillectomy surgery. The patients were randomly allocated to receive either an intranasal dose of clonidine (4 µg/kg) (clonidine group) or an equal volume dose of saline solution (control group) 30 minutes before entering the operating room. The level of anxiety assessed using the m-YPAS score was recorded before premedication, at the time of parent-child separation, and at the time of installation in the operating room. Acceptance of premedication, degree of sedation on entering the operating room as well as agitation on awakening, and sedation on arrival post-anesthesia care unit were noted. Adverse effects were recorded during the surgical procedure and in the postoperative recovery room. Results: the number of patients analyzed was 78 with 39 patients in each group. There were no signification differences in demographic data and premedication acceptance between the two groups. Levels of anxiety before any premedication were similar in the two groups. However, the anxiety level 30 minutes after premedication and in the operating room was significantly lower in the clonidine group (p<0.001). Children who received clonidine showed better sedation on entering the operating room (p=0.002) as well as postoperatively on entering the post-anesthesia unit care (p=0.006). The hemodynamic and respiratory parameters recorded were statistically comparable. Conclusion: intranasal clonidine is an interesting premedication to prevent perioperative children´s anxiety with few side effects.
Assuntos
Ansiolíticos , Clonidina , Adolescente , Criança , Pré-Escolar , Humanos , Ansiedade/prevenção & controle , Clonidina/uso terapêutico , Método Duplo-Cego , Hipnóticos e Sedativos/uso terapêutico , Pré-Medicação/métodos , Estudos Prospectivos , Administração IntranasalRESUMO
Resumen Los parámetros de calidad para endoscopia digestiva alta han introducido indicadores intraprocedimiento, dentro de los cuales la adecuada visibilidad de la mucosa, libre de saliva, moco o burbujas, puede aumentar la posibilidad de detección de lesiones en fase temprana. Sin embargo, el uso de mucolíticos y antiburbujas ha mostrado gran variabilidad de eficiencia según las soluciones, concentraciones, tiempos de exposición y escala de visibilidad aplicados. Objetivos: determinar la efectividad de diferentes soluciones de premedicación para la limpieza de la mucosa digestiva; validar, mediante una prueba de concordancia interobservador, una nueva escala de adecuada visualización de la mucosa (TVMS) para el esófago, estómago y duodeno; y reportar eventos adversos o complicaciones relacionadas con las soluciones utilizadas y los procedimientos realizados. Material y métodos: estudio de cohortes prospectivas comparativas. Se incluyeron 412 pacientes adultos, ASA I y ASA II, para endoscopia diagnóstica bajo sedación consciente, distribuidos en 6 cohortes similares, divididas en dos grupos: no premedicación, 2 cohortes C1 (ayuno de 6 a 8 horas)y C2 (agua 100 mL); premedicación, 4 cohortes C3 a C6 (C3: agua 100 m L + simeticona 1000 mg; C4: agua 100 mL + simeticona 200 mg + N-acetilcisteína 600 mg; C5: agua 100 mL + simeticona 200 mg + N-acetilcisteína 1000 mg; C6: agua 100 mL + simeticona 200 mg + Hedera helix 70 mg). Se ingirió la solución 15 a 30 minutos antes del paso por cricofaríngeo. Se realizó la prueba de Kappa para medir la concordancia interobservador de la escala TVMS. Resultados: De 412 pacientes, 58% fueron de sexo femenino; 23% (136) fue de cohortes C1 y C2 y 67% (276) fue de cohortes C3 a C6. El tiempo medio de exposición a cada solución fue de 24,4 minutos. El volumen de lavado para lograr una adecuada visualización fue significativamente diferente entre ambos grupos: en los pacientes con premedicación se utilizaron 75,6 mL, mientras que en los pacientes sin premedicación se utilizaron 124 mL (p = 0,000), con una calidad de TVMS excelente de 88,7% frente al 41,4%, respectivamente. La cohorte C4 (agua 100 mL + simeticona 200 mg + N-acetilcisteína 600 mg) mostró ser la más efectiva con una diferencia significativa (p = 0,001) frente a C1 (ayuno) y C2 (placebo con agua 100 mL), y también tuvo una eficiencia superior frente a C3, C5 y C6 en su orden. No se presentaron eventos adversos o complicaciones en relación con la endoscopia, la sedación y los productos usados en la premedicación. Conclusiones: la solución más efectiva como premedicación para lograr una excelente visibilidad de la mucosa digestiva correspondió a la cohorte C4 (SIM 200 + NAC 600 + H2O 100 mL). La escala TVMS propuesta es una herramienta muy completa y fácil de aplicar por más de un observador. La premedicación ingerida, con antiburbuja, mucolítico y agua hasta 100 mL, entre 15 y 30 minutos previos a endoscopia, es segura en las condiciones descritas en este estudio.
Abstract Quality parameters for upper gastrointestinal endoscopy have introduced intraprocedural indicators, including adequate mucosal visualization free of saliva, mucus, or bubbles, which may increase the possibility of early-stage injury detection. The use of mucolytics and anti-foaming agents has shown great efficiency variability depending on the type of solution, concentrations, exposure times and visibility scale applied. Objectives: To determine the effectiveness of different premedication solutions for cleaning the digestive mucosa; to validate, by means of an interobserver concordance test, a new scale for the adequate visualization of the mucosa (TVMS) for the esophagus, stomach, and duodenum; and to report adverse events or complications associated with the solutions used and the procedures performed. Material and methods: Prospective, comparative cohort study. 412 adult patients, ASA I and ASA II, were included for diagnostic endoscopy under conscious sedation. They were distributed in 6 similar cohorts and divided into two groups: non-premedication, 2 in C1 (fasting 6 to 8 hours) and C2 (water 100 mL) cohorts; premedication, 4 C3 to C6 cohorts (C3: water 100 mL + simethicone 1000 mg; C4: water 100 ml + simethicone 200 mg + N-acetylcysteine 600 mg; C5: water 100 ml + simethicone 200 mg + N-acetylcysteine 1000 mg; C6: water 100 ml + simethicone 200 mg + Hedera helix 70 mg). The solution was swallowed 15 to 30 minutes passing through the cricopharyngeus muscle. The Kappa test was performed to measure interobserver concordance of the TVMS scale. Results: Of 412 patients, 58% were female; 23% (136) were included in the C1 and C2 cohorts; and 67% (276) were in the C3 to C6 cohorts. The average exposure time to each solution was 24.4 minutes. The wash volume for proper visualization was significantly different between the two groups. In premedicated patients, 75.6 mL of solution were used, while in patients without premedication, 124 mL were used (p = 0.000), with an excellent quality of TVMS of 88.7% versus 41.4%, respectively. The C4 cohort (water 100 mL + simethicone 200 mg + N-acetylcysteine 600 mg) was the most effective with a significant difference (p= 0.001) compared with the C1 (fasting) and C2 (placebo with water 100 mL) cohorts. It also had better efficiency compared to the C3, C5 and C6 cohorts in that order. There were no adverse events or complications associated with endoscopy, sedation, or premedication products. Conclusions: The most effective solution as a premedication to achieve excellent visibility of the digestive mucosa was that used in the C4 cohort (SIM 200 + NAC 600 + H2OR 100 mL). The proposed TVMS scale is a very complete and easy tool to apply by more than one observer. Premedication ingested, with anti-foam, mucolytic and water up to 100 mL, between 15 and 30 minutes before endoscopy, is safe under the conditions described in this study.
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Pré-Medicação , Acetilcisteína , Simeticone , Hedera , Soluções , Endoscopia GastrointestinalRESUMO
Abstract In spite of advances in root canal therapy and better knowledge of pulpal and periapical inflammation, up 40% of endodontic patients report varying degrees of pain. The aim of this present study was to compare the effect of single preoperative dose of ibuprofen or dexamethasone on post-endodontic pain. Sixty volunteers were divided into three groups (n=20 per group): PL, placebo; IB, 400 mg of ibuprofen; and DE, 8 mg of dexamethasone. The primary outcome was the post-endodontic pain intensity measured with a numerical rating scale (4, 8, 12, 24, and 48 h). Secondary outcomes included number of anesthetic cartridges used and consumption of rescue medication. Data were analyzed by one-way ANOVA, chi-square and Kruskal-Wallis tests. There was no significant difference among groups (p>0.05) considering the pain intensity. Only 37% of IB group patients and 28% of DE group patients used some rescue medication. On the other hand, 74% of PL group patients mentioned the consumption of rescue medication; PL group had a statistically significant difference (p<0.05) in comparison with IB and DE groups. The number of anesthetic cartridges used had no statistically significant difference among the groups (p>0.05). Significant differences were not found in the reduction of pain intensity and the number of anesthetic cartridges used. Considering the consumption of rescue medication (secondary outcome), preoperative administration of Ibuprofen or dexamethasone reduces post-endodontic pain and discomfort in comparison with a placebo. Premedication with anti-inflammatory drugs drugs could be contributed to control of the post-endodontic pain, mainly in patients more sensible for pain.
Resumo Apesar dos avanços no tratamento do canal radicular e melhor conhecimento da inflamação pulpar e periapical, 40% dos pacientes submetidos ao tratamento de endodôntico relatam diferentes graus de dor. O objetivo deste estudo foi comparar o efeito pré-operatório (dose única) de ibuprofeno ou dexametasona na dor pós-endodôntica. Sessenta voluntários foram divididos em três grupos (n=20 por grupo): PL, placebo; IB, 400 mg de ibuprofeno; e DE, 8 mg de dexametasona. O desfecho primário foi a intensidade da dor pós-endodôntica medida com uma escala numérica (4, 8, 12, 24 e 48 h). Os desfechos secundários incluíram o número de tubetes anestésicos utilizados e o consumo de medicação resgate. Os dados foram analisados com os testes ANOVA, qui-quadrado e Kruskal-Wallis. Não houve diferença entre os grupos (p>0,05) considerando a intensidade da dor. Apenas 37% dos pacientes do grupo IB e 28% do grupo DE utilizaram alguma medicação resgate. Por outro lado, 74% dos pacientes do grupo PL mencionaram o consumo de medicação resgate; o grupo PL apresentou diferença significativa (p<0,05) em comparação com os grupos IB e DE. O número de tubetes anestésicos utilizados não apresentou diferença significativa entre os grupos (p>0,05). Não encontramos diferença significativa na redução da intensidade da dor e no número de tubetes anestésicos utilizados. Considerando o consumo de medicação resgate (desfecho secundário), a administração pré-operatória de ibuprofeno ou dexametasona reduz a dor pós-endodôntica e o desconforto em comparação com placebo. A pré-medicação com anti-inflamatórios poderia contribuir para o controle da dor pós-endodôntica, principalmente em pacientes mais sensíveis à dor.
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Adulto Jovem , Dexametasona/administração & dosagem , Dexametasona/uso terapêutico , Anti-Inflamatórios não Esteroides/administração & dosagem , Ibuprofeno/administração & dosagem , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/uso terapêutico , Dor Pós-Operatória/tratamento farmacológico , Placebos , Pré-Medicação , Tratamento do Canal Radicular/efeitos adversos , Anti-Inflamatórios não Esteroides/uso terapêutico , Ibuprofeno/uso terapêutico , Administração OralRESUMO
Antivenoms or antitoxins have been effectively used for more than a century. During this time, these products have always proven to be highly effective in the treatment of infections and envenomations. However, antivenoms did not exhibit good safety results in their initial applications. After many improvements, antivenoms have substantially better safety profiles but still have some side effects. Due to the occurrence of adverse reactions, the practice of using premedication with the intent to decrease side effects has become accepted or mandatory in many countries. The drugs used for premedication belong to the histamine H1 antagonist, glucocorticoid and catecholamine groups. Currently, this practice is being questioned due to low or controversial efficacies in clinical assays. In this article, we discuss the causes of adverse reactions, the mechanisms of drugs that block the undesired effects and the results obtained in clinical trials. Although these three families of drugs could have positive effects on reducing adverse reactions, only adrenaline has demonstrated positive results in clinical assays.(AU)
Assuntos
Humanos , Animais , Pré-Medicação/tendências , Mordeduras de Serpentes/terapia , Hidrocortisona/uso terapêutico , Antivenenos/efeitos adversos , Epinefrina/uso terapêutico , Antagonistas dos Receptores Histamínicos/uso terapêutico , Antivenenos/uso terapêuticoRESUMO
Antivenoms or antitoxins have been effectively used for more than a century. During this time, these products have always proven to be highly effective in the treatment of infections and envenomations. However, antivenoms did not exhibit good safety results in their initial applications. After many improvements, antivenoms have substantially better safety profiles but still have some side effects. Due to the occurrence of adverse reactions, the practice of using premedication with the intent to decrease side effects has become accepted or mandatory in many countries. The drugs used for premedication belong to the histamine H1 antagonist, glucocorticoid and catecholamine groups. Currently, this practice is being questioned due to low or controversial efficacies in clinical assays. In this article, we discuss the causes of adverse reactions, the mechanisms of drugs that block the undesired effects and the results obtained in clinical trials. Although these three families of drugs could have positive effects on reducing adverse reactions, only adrenaline has demonstrated positive results in clinical assays.
Assuntos
Humanos , Antagonistas dos Receptores Histamínicos/uso terapêutico , Antídotos/efeitos adversos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Epinefrina/uso terapêutico , Hidrocortisona/uso terapêutico , Pré-Medicação , Intoxicação/complicaçõesRESUMO
Abstract Purpose: To investigate the effects of cyclosporine A on renal ischemia-reperfusion injury during transient hyperglycemia in rats. Methods: In a model of ischemia-reperfusion-induced renal injury and transiently induced hyperglycemia by intraperitoneal injection of glucose, 2.5 g.kg-1, Wistar rats were anesthetized with either isoflurane or propofol and received intravenous cyclosporine A, 5 mg.kg-1, five minutes before reperfusion. Comparison groups were isoflurane and propofol sham groups and isoflurane and propofol ischemia-reperfusion-induced renal injury. Renal tubular cell viability was quantitatively assessed by flow cytometry after cell culture and classified as early apoptosis, necrotic cells, and intact cells. Results: Early apoptosis was significantly higher in isoflurane and propofol anesthetized animals subjected to renal ischemia-reperfusion injury when compared to both cyclosporine A treated and sham groups. Necrosis percentage was significantly higher in propofol-anesthetized animals subjected to renal ischemia-reperfusion injury. The percentage of intact cells was lower in both, isoflurane and propofol anesthetized animals subjected to renal ischemia-reperfusion injury. Conclusion: In a model of ischemia-reperfusion-induced renal injury, cyclosporine A, 5 m.kg-1, administered five minutes before renal reperfusion in rats with acute-induced hyperglycemia under either isoflurano or propofol anesthesia, attenuated early apoptosis and preserved viability in renal tubular cells, regardless of the anesthetic used.
Assuntos
Animais , Masculino , Traumatismo por Reperfusão/prevenção & controle , Ciclosporina/farmacologia , Apoptose/efeitos dos fármacos , Substâncias Protetoras/farmacologia , Hiperglicemia/fisiopatologia , Rim/efeitos dos fármacos , Pré-Medicação , Fatores de Tempo , Traumatismo por Reperfusão/complicações , Distribuição Aleatória , Propofol/farmacologia , Sobrevivência Celular/efeitos dos fármacos , Reprodutibilidade dos Testes , Resultado do Tratamento , Ratos Wistar , Anestésicos Intravenosos/farmacologia , Anestésicos Inalatórios/farmacologia , Citometria de Fluxo , Isquemia/prevenção & controle , Isoflurano/farmacologia , Rim/irrigação sanguínea , Rim/patologia , Necrose/prevenção & controleRESUMO
Atropine (AT) and dipyrone (Dp) induce a delay of gastric emptying (GE) of liquids in rats by inhibiting muscarinic receptors and activating β2-adrenergic receptors, respectively. The objective of the present study was to determine the effects of pretreatment with AT and Dp, given alone or in combination, on the effect of hypoglycemia in the liquid GE in rats. Male Wistar adult rats (280-310 g) were pretreated intravenously with AT, Dp, AT plus Dp or their vehicle and then treated 30 min later with iv insulin or its vehicle (n=8-10 animals/group). Thirty min after treatment, GE was evaluated by determining, in awake rats, the percent gastric retention (%GR) of a saline meal labeled with phenol red administered by gavage. The results indicated that insulin induced hypoglycemia in a dose-dependent manner resulting in a significant reduction in %GR of liquid only at the highest dose tested (1 U/kg). Pretreatment with AT significantly increased %GR in the rats treated with 1 U/kg insulin. Surprisingly, after pretreatment with AT, the group treated with the lowest dose of insulin (0.25 U/kg) displayed significantly lower %GR compared to its control (vehicle-treated group), which was not seen in the non-pretreated animals. Pretreatment with Dp alone at the dose of 40 mg/kg induced an increase in %GR in both vehicle and 0.25 U/kg-treated rats. A higher dose of Dp alone (80 mg/kg) significantly reduced the effect of a marked hypoglycemia induced by 1 U/kg of insulin on GE while in combination with AT the effect was completely abolished. The results with AT suggest that moderate hypoglycemia may render the inhibitory mechanisms of GE ineffective while Dp alone and in combination with AT significantly overcame the effect of hypoglycemia on GE.
Assuntos
Animais , Masculino , Ratos , Anti-Inflamatórios não Esteroides/farmacologia , Atropina/farmacologia , Dipirona/farmacologia , Esvaziamento Gástrico/efeitos dos fármacos , Hipoglicemia/fisiopatologia , Anti-Inflamatórios não Esteroides/administração & dosagem , Atropina/administração & dosagem , Dipirona/administração & dosagem , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Hipoglicemia/induzido quimicamente , Hipoglicemiantes/administração & dosagem , Insulina/administração & dosagem , Modelos Animais , Pré-Medicação , Ratos WistarRESUMO
ABSTRACT Background: The identification of the best strategy to manage cytomegalovirus infection is hampered by uncertainties regarding the risk/benefit ratios of universal prophylaxis versus preemptive therapy, the impact of indirect cytomegalovirus effects and the associated costs. This study investigated the efficacy and safety of targeted preemptive therapy according to perceived risk of cytomegalovirus infection after kidney transplantation. Methods: 144 adult kidney transplant recipients were enrolled in this 12-month study. None received cytomegalovirus pharmacological prophylaxis. Only high risk patients (positive donor/negative recipient (D+/R−), use of induction therapy with antithymocyte globulin, treatment of rejection) received preemptive therapy based on the result of pp65 antigenemia test. Low-risk patients with symptoms related to cytomegalovirus were screened for pp65 antigenemia and treatment initiated if confirmed cytomegalovirus disease. Blinded cytomegalovirus DNAemia was collected weekly during the first three months. Results: The incidence of cytomegalovirus infection was 34% and cytomegalovirus disease was 17%. The incidence was 25% in D+/R−, 69% in those receiving induction with rabbit antithymocite globulin (r-ATG), 46% in those treated for acute rejection, and 28% in low risk patients. By week 3 DNAemia was observed in 30% of patients who were not treated for cytomegalovirus infection/disease, and values ≥2.169 UI/mL showed 61% sensitivity and 85% specificity to detect cytomegalovirus disease (AUC = 0.849 ± 0.042, p < 0.001). Using multivariate analysis, only anti-thymocyte globulin induction was associated with cytomegalovirus infection/disease whereas only expanded donor criteria and renal function at 30 days were associated with renal function 12 months after transplantation. Conclusion: Targeted preemptive therapy in patients with perceived higher risk for cytomegalovirus infection/disease was effective in preventing severe clinical presentation, including tissue invasive and late cytomegalovirus infection. This strategy is associated with direct and indirect cost-savings.
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Transplante de Rim/métodos , Tacrolimo/administração & dosagem , Infecções por Citomegalovirus/prevenção & controle , Imunossupressores/administração & dosagem , Ácido Micofenólico/administração & dosagem , Pré-Medicação , Estudos Prospectivos , Fatores de Risco , Estudos de Coortes , Transplante de Rim/efeitos adversosRESUMO
Abstract Dual antiplatelet therapy is a well-established treatment in patients with non-ST elevation acute coronary syndrome (NSTE-ACS), with class I of recommendation (level of evidence A) in current national and international guidelines. Nonetheless, these guidelines are not precise or consensual regarding the best time to start the second antiplatelet agent. The evidences are conflicting, and after more than a decade using clopidogrel in this scenario, benefits from the routine pretreatment, i.e. without knowing the coronary anatomy, with dual antiplatelet therapy remain uncertain. The recommendation for the upfront treatment with clopidogrel in NSTE-ACS is based on the reduction of non-fatal events in studies that used the conservative strategy with eventual invasive stratification, after many days of the acute event. This approach is different from the current management of these patients, considering the established benefits from the early invasive strategy, especially in moderate to high-risk patients. The only randomized study to date that specifically tested the pretreatment in NSTE-ACS in the context of early invasive strategy, used prasugrel, and it did not show any benefit in reducing ischemic events with pretreatment. On the contrary, its administration increased the risk of bleeding events. This study has brought the pretreatment again into discussion, and led to changes in recent guidelines of the American and European cardiology societies. In this paper, the authors review the main evidence of the pretreatment with dual antiplatelet therapy in NSTE-ACS.
Resumo A indicação de dupla terapia antiplaquetária para o tratamento da síndrome coronariana aguda sem elevação do ST está bem estabelecida e é recomendação classe I (Nível de Evidência A) nas atuais diretrizes nacionais e internacionais. No entanto, essas mesmas diretrizes não são muito claras e consensuais quanto ao melhor momento para utilização do segundo antiplaquetário. As evidências sobre este tema são conflitantes e, após mais de uma década do uso do clopidogrel neste cenário, ainda há discussão se o pré-tratamento com dupla terapia antiplaquetária teria benefício de maneira rotineira, ou seja, quando aplicada sem conhecer a anatomia coronária. A recomendação de tratamentoupfront com clopidogrel na síndrome coronariana aguda sem elevação do ST se baseia em redução de eventos não fatais identificados em estudos que utilizavam estratégia conservadora, com eventual estratificação invasiva tardia, vários dias após o evento agudo. Essa abordagem é bastante diferente da que é feita atualmente, tendo em vista os benefícios já demonstrados da estratégia invasiva precoce nos pacientes de risco intermediário/alto. O único ensaio clínico randomizado que testou a hipótese do pré-tratamento na síndrome coronariana aguda sem elevação do ST sob a atual estratégia invasiva precoce utilizou o antiplaquetário prasugrel e mostrou que não houve benefício em redução de eventos isquêmicos, tendo, por outro lado, aumentado o risco de eventos hemorrágicos. Este estudo trouxe novamente o pré-tratamento à discussão e modificou recomendações nas atuais diretrizes das sociedades americana e europeia de cardiologia. Neste artigo, os autores apresentam uma revisão sobre as principais evidências do pré-tratamento com dupla terapia antiplaquetária na síndrome coronariana aguda sem elevação do ST.
Assuntos
Humanos , Síndrome Coronariana Aguda/tratamento farmacológico , Inibidores da Agregação Plaquetária/uso terapêutico , Pré-Medicação/métodos , Ensaios Clínicos como Assunto , Metanálise como Assunto , Guias de Prática Clínica como Assunto , Fatores de Tempo , Ticlopidina/análogos & derivados , Ticlopidina/uso terapêuticoRESUMO
INTRODUCTION. The transfusion therapy is an intervention that saves life or quickly improves a serious condition, however, may lead to complications acute or delayed; It includes risks that can have serious or fatal consequences despite the strict controls that precede the transfusion. It is one of the greatest achievements of modern medicine, which has allowed lower mortality, prolong and improve the quality of life for many people with different disorders. METHODS. We performed a systematic search of articles at Pubmed, care, and blood transfusion Web sites (Lilacs, Elsevier, Scielo, Medigraphic, who, Imbiomed) related to the theme were limited to humans, documents published during the last 5 years, in English or Spanish, the clinical practice guidelines document type and validated the MeSh terms used blood transfusion. The strategy of search gave 488 results, of which are used 20 documents in the preparation of the Guide.RESULTS. Within them main strategies for it security in the therapy transfusion this it training to the personal, the verification of the transfusion correct with the hemocomponente correct: component, amount, speed of transfusion, type of filter and the need of premedication. CONCLUSIONS. The main nursing intervention in this guide highlight double effort in their care to the patient, transfusions, is processes of high responsibilities that demands extreme care, additional interventions of his pathology, and are aimed at improving health conditions
INTRODUCTION. The transfusion therapy is an intervention that saves life or quickly improves a serious condition, however, may lead to complications acute or delayed; It includes risks that can have serious or fatal consequences despite the strict controls that precede the transfusion. It is one of the greatest achievements of modern medicine, which has allowed lower mortality, prolong and improve the quality of life for many people with different disorders. METHODS. We performed a systematic search of articles at Pubmed, care, and blood transfusion Web sites (Lilacs, Elsevier, Scielo, Medigraphic, who, Imbiomed) related to the theme were limited to humans, documents published during the last 5 years, in English or Spanish, the clinical practice guidelines document type and validated the MeSh terms used blood transfusion. The strategy of search gave 488 results, of which are used 20 documents in the preparation of the Guide. RESULTS. Within them main strategies for it security in the therapy transfusion this it training to the personal, the verification of the transfusion correct with the hemocomponente correct: component, amount, speed of transfusion, type of filter and the need of premedication. CONCLUSIONS. The main nursing intervention in this guide highlight double effort in their care to the patient, transfusions, is processes of high responsibilities that demands extreme care, additional interventions of his pathology, and are aimed at improving health conditions
Introdução. A terapia de transfusão é uma intervenção que salva a vida ou melhora rapidamente uma condição séria, no entanto, pode levar a complicações agudas ou atrasadas; Ele inclui os riscos que podem ter consequências graves ou fatais, apesar dos controles estritos que precedem a transfusão. Um deles é grandes conquistas da medicina moderna, que permitiu diminuir a mortalidade, prolongar e melhorar a qualidade de vida de muitas pessoas com diferentes transtornos. MÉTODOS. É realizada uma busca sistemática dos artigos no Pubmed, cuidados e sites da Web (Lilacs, Scielo, Elsevier, Medigraphic, quem e Imbiomed) relacionadas com o sangue de transfusão do assunto é limitada ao ser humano, documentos publicados durante os últimos 5 anos, em idioma inglês ou espanhol, o tipo de documento de guias de prática clínica e é usado termos validado a malha transfusão de sangue. A estratégia de busca foi 488 resultados, dos quais 20 documentos foram utilizados na elaboração do guia. RESULTADOS. Dentro as principais estratégias para a segurança na transfusão terapia está fornecendo treinamento para os funcionários, a verificação da transfusão correta com o hemocomponente correto: componente, a quantidade, a velocidade de transfusão, o tipo de filtro e a necessidade de pré-medicação. CONCLUSÕES. Intervenções de enfermagem principal neste esforço de duplo destaque guia em seus cuidados ao paciente, desde a transfusão do ato em si, é um processo de alta responsabilidade que demandam cuidados de fim, adicional a eles próprios da sua patologia, intervenções e destinam-se a melhorar as condições de saúde
Assuntos
Humanos , Reação Transfusional , Hemoderivados , Pré-MedicaçãoRESUMO
Sedation for procedures performed outside the operating room (OR) doubles the mortality rate of procedures perfomed in the OR. The levels of sedation are: anxiolysis, moderate sedation, deep sedation, and general anesthesia; passing from one level to the next depending on the dose of the drug, the period of administration, the use of concomitant drugs and type of stimulus. Prevention of complications is achieved by reducing expectations, assessing and monitoring the patient, and awaiting for the effects of the drugs. Respiratory complications are the main cause of morbi-mortality associated to the use of sedation: respiratory depression induced by drugs, airway obstruction and laryngospasm. Cardiovascular complications are directly related to the level of sedation, but can also be secondary to hypoxemia, vagovagal reflexes due to distention of the gastric tract, hypotension, arrhythmia, arterial hypertension and myocardial ischemia; and anaphylaxis. Other complications can be: adverse reaction to drugs, bronchopulmonary aspiration, eye damage, mistakes in drug administration, respiratory failure, and prolonged amnesia.
La sedación para procedimientos fuera de pabellón tiene el doble de mortalidad que los pacientes de pabellón. La profundidad de sedación se divide en Ansiolisis, Sedación Moderada, Sedación Profunda y Anestesia General; pasando de un estado a otro dependiendo de dosis de droga, tiempo de administración, uso de otras drogas y estímulo. La prevención de las complicaciones se logra: bajando las expectativas, evaluando a los pacientes, monitorizando y esperando el efecto de los medicamentos. Las complicaciones respiratorias: Son la primera causa de morbimortalidad asociada al uso de sedación: depresión respiratoria inducida por drogas, obstrucción de vía aérea y espasmo laríngeo. Las complicaciones cardiovasculares: están en directa relación con la profundidad de sedación, pero pueden producirse secundariamente a hipoxemia, reflejos vagales por distensión del tubo digestivo: hipotensión, arritmias, hipertensión arterial e isquemia miocárdica; y anafilaxia. Otras Complicaciones pueden ser: reacción adversa a drogas, aspiración broncopulmonar, daño ocular, errores de administración de fármacos, tórax leñoso, amnesia prolongada.